Objectives: Rectum cancer is a type of colorectal cancer. Its etiology and etiopathogenesis are similar to other colon diseases. However, it is differentiated from other colon tumors because of its different anatomy and treatment. We aimed to evaluate the inflammatory based indices value for predicting prognosis of rectum cancer patients who treated with neoadjuvant chemoradiotherapy. Methods: We retrospectively collected the data of 80 operated rectum adenocarcinoma patients who were treated neoadjuvant chemoradiotherapy between 2013 and 2018 in Umraniye Research and Training Hospital and Acıbadem University Medical Oncology Outpatient Clinic. Peripheral venous blood samples were collected for analysis of lymphocyte (Lym), neutrophile (Neu) and platelet (Plt) numbers, and, hemoglobin levels at the time of diagnosis. NLR, PLR, and SII were investigated as prognostic factors for disease free survival. Results: This study included 80 rectum cancer patients and 55 were male (68.8%). Median age was 56 (range 22 to 83 years). According to clinical parameters, histopathological types were adenocarcinoma in 75 (93.8%) patients and mucinous adenocarcinoma in 5 (6.2%) patients). In multivariate analysis, PLR were found to be independent prognostic factors for disease free survival (p=0.02). Conclusion: According to our study, we suggest that high levels of PLR at the time of diagnosis can be used as a predictive biomarker for rectum patients who may show relapse predispositi
Corresponding Author: Atakan Demir